Compare JD.Com Inc (JD) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JD.Com Inc vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? JD.Com Inc trades at $26.99 (market cap $36.51B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.16B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is the larger of the two by market cap, and JD.Com Inc pays the higher dividend (3.7%). Which is the better fit depends on your goals — on Pluang, investors hold JD.Com Inc for 85 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| JD | TAK | |
|---|---|---|
Market Cap | $36.51B | $58.16B |
Volume | 7,051,146 | 2,467,530 |
Sector | Consumer Cyclical | Health |
52-Week High | $34.53 | $19.05 |
52-Week Low | $25.19 | $13.23 |
Typical Hold Time | 85 Days | 0 Days |
Enterprise Value | $19.16B | $86.04B |
Dividend Yield | 3.7% | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JD.com trades at $26.91, up 1.55% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $0.93 surpassing the $0.86 estimate. The company maintains robust fundamentals, including a low P/S ratio of 0.2 and a solid cash position of $234 billion as of 2024. Positive developments include potential EU approval for the $2.5 billion Ceconomy acquisition, signaling strategic expansion.
The outlook for JD.com is positive, supported by undervaluation metrics and strong free cash flow, though risks include revenue declines and regulatory scrutiny. With 69.57% of analysts rating it a Buy and a consensus price target of $35.86, the stock offers significant upside potential, but investors should monitor competitive pressures and macroeconomic headwinds in the Chinese market.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
